Table 1.
Characteristic | Rituximab (2 × 1000 mg) PRN (n = 257) | Rituximab (2 × 1000 mg) TT (n = 236) |
---|---|---|
Gender: female, % | 78 | 82 |
Age, mean (s.d.) years | 52 (11.3) | 52 (12.5) |
Median disease duration (IQR), years | 8.5 (3.9–14.9) | 3.6 (1.5–9.9) |
No. of previous DMARDs, mean (s.d.) | 2.0 (1.20) | 1.2 (1.19) |
Concomitant steroids, % | 49 | 48 |
Concomitant NSAIDs, % | 53 | 56 |
Swollen joint count (0–66), mean (s.d.) | 20 (10.8) | 19 (10.2) |
Tender joint count (0–68), mean (s.d.) | 32 (15.1) | 30 (14.8) |
CRP, mean (s.d.), mg/l | 3.1 (3.44) | 2.1 (2.44) |
ESR, mean (s.d.), mm/h | 42.7 (24.2) | 45.1 (27.1) |
HAQ-DI (0–3 range), mean (s.d.) | 1.7 (0.57) | 1.6 (0.64) |
DAS-28-ESR, mean (s.d.) | 6.7 (0.95) | 6.6 (1.03) |
RF+, % | 81 | 73 |
Anti-CCP+, % | 78 | 80 |
Data are mean (±SD) or number (%) unless otherwise stated. Anti-CCP, anti-cyclic citrullinated peptide; NSAIDs, non-steroidal anti-inflammatory drugs; RF, rheumatoid factor.